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IMMUNOBIOLOGY
Molecular characterization and expression of a novel human leukocyte
cell-surface marker homologous to mouse Ly-9
Miguel Angel de la Fuente, Victoria Tovar, Neus Villamor, Nuria Zapater, Pilar Pizcueta, Elias Campo, Jaime Bosch, and Pablo Engel
Ly-9 is a mouse cell-surface glycoprotein
that is selectively expressed on thymo-
cytes and on mature T and B lympho-
cytes. Ly-9 belongs to the CD2 subset of
the immunoglobulin superfamily, an emerg-
ing family of cell signaling receptors.
Recently, a partial human Ly-9 comple-
mentary DNA (cDNA) sequence has been
described. Full-length cDNA clones were
isolated that included the initiation codon,
the sequence encoding the full signal
peptide, and 14 amino acids more in the
cytoplasmic domain than in the previ-
ously reported clone. The predicted extra-
cellular domain of human Ly-9 contains 4
immunoglobulinlike domains, similar to
those in mouse Ly-9. Northern blot analy-
sis revealed that the human Ly-9 messen-
ger RNA (2.6 kb) is expressed predomi-
nantly in lymph node, spleen, thymus,
and peripheral blood leukocytes. Four
monoclonal antibodies (mAbs) were
raised against human Ly-9 by immunizing
mice with the pre-B-cell line 300.19 stably
transfected with human Ly-9 full-length
cDNA. These mAbs strongly stained the
surfaces of cells transfected with human
Ly-9 cDNA but not of untransfected cells.
Human Ly-9 expression was restricted to
T and B lymphocytes and thymocytes,
with the highest levels of expression on
CD41CD82 and CD42CD81 thymocytes.
Monocytes, granulocytes, platelets, and
red blood cells were uniformly negative
for Ly-9. These mAbs immunoprecipi-
tated major polypeptides of 120 kd from
the transfected cells and 120 kd and 100
kd from B-cell line Daudi, probably be-
cause of the cell-surface–expressed iso-
forms. These data demonstrate that hu-
man Ly-9 is a new marker for the study of
normal and malignant leukocytes. (Blood.
2001;97:3513-3520)
© 2001 by The American Society of Hematology
Introduction
Several cell-surface molecules, termed accessory molecules, coop-
erate with antigen-specific receptors by participating in cell adhe-
sion between lymphocytes and other cells or by contributing to cell
signal transduction.1 A significant number of these molecules
belong to the immunoglobulin superfamily (IgSF).2
Mouse Ly-9 is a cell-surface glycoprotein expressed on the cell
surfaces of thymocytes and mature B- and T-lymphocytes. It was
initially described as an alloantigenic marker of lymphocyte
differentiation, and it has 2 alleles.3,4 Ly-9.1 is found in most mouse
strains, whereas Ly-9.2 is only found in C57BL/6 and related
strains (C57BR, C57L, and C58).5,6 Because Ly-9 is broadly
expressed during lymphoid differentiation, monoclonal antibodies
(mAbs) against the Ly-9.1 allotype are used as markers to examine
the contribution of embryonic stem-derived cells to lymphoid
development in RAG-1– and RAG-2–deficient blastocyst comple-
mentation studies.7-9 These mAbs are also used to test the per-
centage of chimerism in allophenic mice.10
Ly-9 has also been reported to be a member of the IgSF with
structural features that place it within the CD2 family, which
includes CD48, CD58, 2B4, CD84, and CDw150.11,12 Members of
this family are expressed by various leukocytes and are involved in
the activation of lymphocytes and natural killer cells.13 Unlike
other CD2 family members, Ly-9 has 4 rather than 2 IgSF domains
in its extracellular part. Domains 1 and 3 are similar, as are domains
2 and 4, suggesting that Ly-9 arose from a progenitor with one V
and one C2 domain.11 Ly-9 has the highest similarity to the
cell-surface molecules CD84 and CD48.14,15 The Ly-9 locus lies
close to the CD48, 2B4, CDw150, and CD84 genes on both mouse
and human chromosome 1. These genes may be the result of gene
duplication from a common ancestor, with a second duplication
event leading to the 4-domain structure of Ly-9.14-16
The function of this leukocyte-specific cell-surface molecule is
unknown. However, analysis of the cytoplasmic tail of Ly-9 reveals
various motifs identical to those observed in several receptors
involved in cell signaling.17 The cytoplasmic tail of Ly-9 contains 2
unique tyrosine-based motifs (with the consensus amino acid
sequence TxYxxV/I) also found on the cytoplasmic domain of
SLAM (CDw150), 2B4, and CD84. This is critical for the binding
of SLAM and 2B4 to a protein called SLAM-associated protein
(SAP), which is mutated in the immunodeficiency X-linked
lymphoproliferative syndrome.18-20 It has been proposed that
impaired signaling by these receptors is responsible for this
immunodeficiency.13,18
Sandrin et al21 have reported a partial human Ly-9 complemen-
tary DNA (cDNA) sequence (HumLy-9) lacking the sequence
encoding the amino-terminal portion of the signal peptide and part
of the cytoplasmic tail. To date, human Ly-9 has not been
serologically, biochemically, or functionally characterized. We
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have used several probes to isolate homologous full-length human
Ly-9 clones. Mice were immunized with cells transfected with the
isolated cDNA to raise mouse mAbs against human Ly-9. These
mAbs were used to characterize the human Ly-9 glycoprotein and
its surface expression on normal and malignant cells.
Materials and methods
Isolation of human and Ly-9 cDNA clones
A cDNA library from the human Burkitt lymphoma cell line Raji in lgt11
(Clontech Laboratories, Palo Alto, CA) was used to isolate cDNA using a
mixture of various polymerase chain reaction (PCR)-generated probes
corresponding to sequences reported for mouse and human surface
molecule Ly9.11,21 The following primers were used to generate the probes:
human primers (sense oligonucleotide 59-CTGCTCATGGGACTAAGAG-
39, antisense oligonucleotide, 59-TCTGGAGGCTCCTGGATCTGTAC-
39), corresponding to the first and second immunoglobulinlike domains21;
mouse primers (sense oligonucleotide 59-AGGCTCTTGCTTTAGTATTCT-
39, antisense oligonucleotide, 59-ATTGCCAGATGCGGACAGGTT-39),
corresponding to the first and second immunoglobulinlike domains.11 PCR
probes were obtained from cDNA produced by reverse transcription
(RT)-PCR of total RNA isolated from mouse peripheral lymph nodes and
human peripheral blood leukocytes using a First-Strand cDNA Synthesis
Kit for RT-PCR avian myeloblastis virus (AMV) and the Taq polymerase
Expand High Fidelity (Boehringer Mannheim, Mannheim, Germany)
according to the manufacturer’s instructions. PCR products were purified,
subcloned into pSP64 vector (Promega, Madison, WI), and sequenced.
Random priming labeling with [a-32P] CTP was carried out using the
Ready-To-Go DNA labeling kit (Pharmacia Biotech, Uppsala, Sweden).
Filter hybridization was performed in ExpressHyb hybridization solution
(Clontech) according to the manufacturer’s instructions. Plaques that were
positive on duplicate filters were picked up, and the phage insert DNA was
isolated and subcloned in SP64 vector. Nucleotide sequences were deter-
mined by dideoxynucleotide chain termination using the T7 Sequencing Kit
(Pharmacia Biotech). Sequence uniqueness and homology with other
molecules were tested using BCM Search Launcher analysis software
(Human Genome Center, Baylor College of Medicine, Houston TX).
Putative leader peptides and transmembrane regions were identified using
the PSORT program (Nenta Nakai, Institute for Molecular and Cellular
Biology, Osaka University, Japan). The numbering system used in this
paper refers to the amino acid sequence of the mature protein after cleavage
of the leader peptide.
RT-PCR of human Ly-9 from transfected cells and cell lines was
performed using the following oligos: 59-GCTAGCATGAGTCAGCTG-
CAAATATTCTCT-39 and 59-GCAGCAGCTGCTTTTCCTTTCAGGT-
GAA-39. PCR products were cloned using the TOPO subcloning kit
(Invitrogen, Groningen, The Netherlands) and sequenced.
5* rapid amplification of cDNA ends procedure
The 59 rapid amplification of cDNA ends (RACE) was performed using the
Marathon-Ready cDNA kit (Clontech Laboratories, Palo Alto, CA) accord-
ing to the manufacturer’s instructions. Human lymph node cDNA, which
had been ligated with an adaptor, was also from Clontech. Antisense primer
59 GAACAGGGTGAATTCCTCCTCAGTGGTG-39, corresponding to the
first immunoglobulinlike domain of human Ly-9, was used. PCR was
carried out with an anchor primer and a nested primer corresponding to
human Ly-9 sequence 59-CCTCCTCAGTGGTGACTTCAAAATTCC-39.
One product was cloned and sequenced as described.
Northern blot analysis
Northern blot analysis was performed with nylon membranes from
Clontech Laboratories (Multiple Tissue Northern Blot). Two micrograms
poly A1 RNA from several tissues (spleen, lymph node, thymus, appendix,
peripheral leukocytes, bone marrow, fetal liver, heart, brain, placenta, lung,
liver, skeletal muscle, kidney, and pancreas) was blotted after running on a
denaturing formaldehyde 1.2% agarose gel. Northern blot membranes were
hybridized with a 222-bp probe from immunoglobulinlike domain 1 of the
human Ly9 clone and a 2000-bp human a-actin cDNA as control probe.
Hybridization was performed according to the manufacturer’s instructions.
Membranes were autoradiographed for 72 hours (human Ly9) or 4 hours
(a-actin) at 280°C using 2 intensifying screens.
Cells
Cell lines were cultured in RPMI 1640 media (Gibco-BRL, Gaithersburg,
MD) supplemented with 10% fetal calf serum (FCS), L-glutamine,
streptomycin, and penicillin. Cell lines Raji, Daudi, Jurkat, JM1, K562,
HL60, RPMI, CESS, and U937 were from the American Tissue Culture
Collection (Rockville, MD). The BEN cell line was obtained by the
transformation of peripheral blood leukocytes with Epstein-Barr virus.
Cultures of all cell lines were split the day before analysis. Blood
leukocytes were isolated by Ficoll-Hypaque density gradient centrifugation
of heparinized blood from healthy donors. Mononuclear cells were
activated with 10 mg/mL phytohemagglutinin (Sigma, St Louis, MO), 5
ng/mL and 10 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma), and
500 nM calcium ionophore A231187 (Sigma) for 72 hours at a concentra-
tion of 2 3 106 cells /mL in RPMI 10% FCS. Erythrocytes were isolated
from the red cell pellet after Ficoll-Hypaque sedimentation of blood.
Thymus and tonsil lymphocytes were isolated as described.22,23 Bone
marrow cells were obtained from 3 patients with anemia. Acute leukemias
were classified on the basis of morphologic, cytologic, immunologic, and
cytogenetic criteria described by French-American-British and European
Group for the Immunological Classification of Leukemias (EGIL) groups
and the World Health Organization (WHO).24 The diagnosis of lymphopro-
liferative disorders was based on the Revised European-American Classifi-
cation of Lymphoid Neoplasms (REAL) and WHO classification.25
All cells and tissues were obtained in accordance with protocols
approved by the Ethics Committee of the Hospital Clı´nic of Barcelona.
Informed consent was obtained from all the patients.
Cell transfection
Stably transfected cells were produced using the full-length human Ly-9
cDNA (1965 bp) cloned into the SmaI site of the pCI-neo expression vector
(Promega) and the Ly-9 cDNA clone that lacked the third immunoglobulin-
like domain. With the use of a Gene Pulser II Apparatus (Bio-Rad,
Hercules, CA), 8 3 106 300.19 cells were transfected with 8mg linearized
vector by electroporation (280 V, 950 mF). The cells were then plated in
flat-bottomed 96-well tissue plates by limiting dilution, and stable transfec-
tants were selected using 1.2 mg/mL G418 (Gibco-BRL). Sixteen clones
from the transfection were examined by Northern blot, using a 222-bp
fragment as probe. Clone 13, which expressed the highest level of message,
was used in this study and was maintained in the presence of the
selecting drug.
COS cells were transfected with the full-length human Ly9 cDNA
subcloned in the pCI-neo expression vector and human Ly9-Fc chimeric
constructs according to the DEAE-dextran method.26 Cell-surface expres-
sion was examined after 48 hours by immunohistochemical analysis
as described.27
Monoclonal antibodies
HLy-9.1.25 (IgG1, k), HLy-9.1.38 (IgG1, k), HLy-9.1.77 (IgG2a, k), and
HLy-9.1.84 (IgG1, k) mAbs were generated by fusing NS-1 myeloma cells
with spleen cells from BALB/c mice immunized twice with the mouse
pre-B-cell line 300.19, stably transfected with the full-length cDNA (clone
13). Hybridomas producing mAb reactive to transfected but not untrans-
fected cells were subcloned twice and used to generate concentrated
supernatant obtained from the culture of the hybridomas in Integra CL 350
flasks (Integra Biosciences AG, Wallisellen, Switzerland). Monoclonal
antibody isotypes were determined using the Isotyping Kit (Boehringer
Mannheim). The mAbs were purified using an Affi-Gel Protein A MAPS II
kit (Bio-Rad, Hercules, CA). Purified mAbs were biotinylated using
Biotinamidocaproate N-hydroxysuccinimide ester (Sigma). Other mAbs
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used in this study were CD4-FITC, CD8-perCP, CD19-FITC, CD19-PE,
CD19-perCP, CD38-PE, CD56-FITC, CD16-PE, and CD3-APC (Becton
Dickinson, San Jose, CA). Fluorescein isothiocyanate (FITC)-conjugated
antisera against human IgM and mouse IgG were from Caltag (Burlin-
game, CA).
Immunofluorescence analysis
Cells were kept at 4°C and examined immediately after isolation.
Indirect immunofluorescence analysis of viable cells was carried out
after the cells were washed twice (PBS containing 2% FCS and sodium
azide 0.05%). Cells were then incubated for 20 minutes on ice, and each
mAb was diluted to the optimal concentration for immunostaining.
Isotype-matched murine mAbs that were unreactive with human leuko-
cytes were used as negative controls. After they were washed, the cells
were incubated for 20 minutes at 4°C with Avidin conjugated with FITC,
phycoerythrin (PE), perCP, or Cy-Chrome (Pharmingen; Becton Dickin-
son). Single-, double-, triple-, and quadruple-color immunofluorescence
analyses were performed on a FACSCalibur (Becton Dickinson Immuno-
cytometry Systems, San Jose, CA). Cells with forward and light scatter
properties of monocytes and granulocytes were analyzed from the blood
samples. At least 5000 cells per sample were analyzed.
Cell-surface biotinylation and immunoprecipitation
Cells (40 3 106) were washed 3 times in phosphate-buffered saline (PBS),
resuspended in 800 mL saline, and surface-labeled with 200 mL biotin 1
mg/mL (Sigma) for 20 minutes at 4°C. After 1 wash in RPMI media with
10% FCS and 4 washes in PBS, the cells were lysed in 1 mL buffer
containing 0.5% (vol/vol) NP40 and protease inhibitors as described.28
Immunoprecipitations were carried out using 15 mg mAbs. Cell lysates
were precleared 3 times for 2 hours using 50 mL (50% vol/vol) mouse
immunoglobulin-coated beads at 4°C. Cell lysates were precleared again
overnight. The precleared lysate was then incubated with 50mL CD84
mAb-coated beads (50% vol/vol) or mouse immunoglobulin-coated beads
with constant rotation at 4°C for 18 hours. Immunoprecipitates were
washed and analyzed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) as described.28 Samples were run in the
presence or absence of 5% 2-mercaptoethanol. Mr was determined using
prestained standard molecular weight markers (Gibco/BRL). Proteins were
transferred by electroblotting with glycine transfer buffer (96 mM glycine,
12 mM Tris base in 10% methanol, pH 8.3) to PVDF membranes
(Immobilon; Millipore, Boston, MA). After 2 hours of incubation at room
temperature with blocking solution (10% nonfat milk in PBS), avidin
peroxidase (100 ng/mL) (Sigma) was added for 1 hour. Membranes were
washed with PBS with 0.1% Tween 20, and the blot was developed using
enhanced chemiluminescence reagent (Amersham International, Little
Chalfont, United Kingdom).
Results
Isolation and sequencing of cDNA clones encoding human Ly-9
Four different cDNA clones were isolated from a lgt11 cDNA
library constructed using RNA isolated from the human Raji cell
line. Only one of these clones, measuring approximately 2100 bp
and containing an entire sequence, was selected for further
analysis. This clone included the initiation codon and sequence
encoding the full signal peptide and 14 more amino acids in the
cytoplasmic domain than the previously reported clone.21 The
sequence of the selected clone revealed an ORF encoding a 608
amino acid protein with a molecular mass of 65 kd after cleavage of
the signal peptide. The amino acid sequence was identical to mouse
Ly-9 in 51% (73% if conserved amino acid substitutions are
considered) (Figure 1), showing that it is the human homologue for
this molecule. The leader peptide comprised 47 amino acids, as in
mouse Ly-9 cDNA (Figure 2). Analysis of 50 clones obtained by 59
RACE from a human lymph node library showed that all presented
the same leader peptide (data not shown).
The extracellular part of the molecule consisted of 4
immunoglobulinlike domains similar to those in mouse Ly-9.12
The first and third were V-like domains that lacked the usually
conserved disulfide bonds between the b sheets. The second and
fourth had the structural features of an IgSF-truncated C2 set
domain with 2 putative disulfide bonds. One of the isolated
clones (HLy-9 no. 2) lacked the sequence corresponding to the
fourth immunoglobulinlike domain (Figure 1.). The extracellu-
lar domains contained 7 putative N-linked glycosylation sites, 5
of which were preserved at the same position in mouse and
human Ly-9. The human Ly-9 cytoplasmic domain was also
homologous to that of mouse Ly-9 (28% identity). The cytoplas-
mic domain contained 179 amino acids, 15 threonines, 16
serines, and 6 tyrosines, 5 of which were preserved in human
and mouse and could be sites of phosphorylation. Tyrosines
were present in 5 Tyr-containing motifs (Y-x-x-I/V) suggestive
of SH2-binding sites. In contrast with results reported else-
where, mouse and human cytoplasmic tails seemed to have the
same number of amino acids (Figure 2.). Our results and
previous reports differed by 14 amino acids, suggesting that
these amino acids are alternatively spliced.
Expression of human Ly-9 messenger RNA in several tissues
Expression of human Ly-9 messenger RNA (mRNA) from several
tissues was analyzed by Northern blot. An mRNA species of
approximately 2.6 kb was detected in all lymphoid tissues tested,
which included spleen, lymph node, thymus, appendix, peripheral
leukocytes, and fetal liver, but not in bone marrow (Figure 3A-B).
Slightly shorter bands, between 2.3 and 2.6 kb, might have
represented an alternatively spliced mRNA. No hybridizing mRNA
was detected in the heart, brain, lung, liver, skeletal muscle, or
kidney (Figure 3). Placenta was the only nonlymphoid tissue with
significant levels of mRNA.
Generation of mAb against human Ly-9
Four mAbs were obtained by immunizing mice with a clone of
mouse pre-B-cell line 300.19 transfected with the full-length
cDNA that was shown to contain the highest amount of mRNA by
Northern blot. Each mAb reacted with 300.19 and COS transfected
with human Ly-9; none reacted with untransfected parenteral cells
(Figure 4, and data not shown).
Cell-surface staining of human cells, cell lines, and leukemias
with anti–human Ly-9 monoclonal antibodies
Anti–human Ly-9 mAbs were biotinylated and used to stain blood
cells, lymphocytes isolated from thymus, bone marrow, blood and
tonsil, and a large panel of lymphoid and myeloid cell lines.
Anti–human Ly-9 mAb stained the cell surface of a third of the
CD41CD81 double-positive thymocytes (Figure 5). The intensity
of Ly-9 expression was higher on CD41CD82 and CD42CD81
single-positive thymocytes. Some CD42CD82 thymocytes ex-
pressed human Ly-9, though according to 4-color flow cytometry,
most of these cells expressed CD3, whereas some staining was also
seen on the CD32CD42CD82 triple-negative cells (Figure 6).
Human Ly-9 cell-surface expression correlated well with that of
CD69. However, human Ly-9 appeared earlier than CD69 on the
cell surfaces of the thymocytes because a significant number of
Ly-9–positive thymocytes did not express CD69 (Figure 7).
Staining of peripheral blood leukocytes showed that human
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Ly-9 was expressed on mature lymphocytes but absent on
monocytes, granulocytes, erythrocytes, and platelets, indicating
that its expression was restricted to lymphocytes (Figure 8, and
data not shown). CD161CD561 natural killer cells expressed
low amounts of this protein (Figure 8). Mature T lymphocytes
expressed higher levels of human Ly-9 than B lymphocytes
(Figure 8). Bone marrow CD19 B cells expressed significant
amounts of human Ly-9, but expression was lower than that
found on peripheral blood B lymphocytes (Figure 8). Human
Ly-9 expression significantly increased on the surfaces of
lymphocytes after 24-hour activation with PMA (data not
shown). Three- and 4-color immunofluorescence staining of
tonsil lymphocytes showed that the expression of human Ly-9
was higher on T lymphocytes than on B lymphocytes (Figure 9).
IgD2, CD381 B lymphocytes, corresponding to germinal center
cells, expressed more human Ly-9 than IgD1, CD382 mantel
zone B lymphocytes (Figure 9). Expression on the other
Figure 1. Nucleotide sequence and predicted amino
acid sequence of human Ly-9. Potential N-linked glyco-
sylation sites are in italics. Signal peptide and transmem-
brane regions are double underlined. The asterisk indi-
cates the termination codon. The sequence corresponding
to the fourth domain is underlined. In box sequence
splicing in the cytoplasmic tail. The GenBank accession
number of the cDNA clone is AF244129.
Figure 2. Amino acid comparison of leader peptide and cytoplasmic tail of
mouse and human Ly-9. The upper sequence corresponds to mouse Ly-9 and the
lower to human Ly-9. Identical amino acids are indicated by 2 dots; conserved
substitutions are indicated by 1 dot. Gaps are indicated by a line to allow optimal
alignment of the sequences. Dark lines indicate amino acids not present in previously
published sequences.7,12 The GenBank accession number of the mouse cDNA
sequence is AF244131.
Figure 3. mRNA analysis for human Ly-9. Northern blot analysis showing the
expression of human Ly-9 mRNA in lymphoid and nonlymphoid tissues. Autoradiogra-
phy was scanned with a Bio-Profile densitometer (Vilber Lourmat, Marne la Vallee,
France).
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subpopulation of tonsil B cells was identical to that found on
IgD1, CD382 cells (data not shown).
The Burkitt lymphoma B-cell lines (Daudi and Raji) and the
Epstein-Barr virus–transformed B-cell lines (CESS and BEN)
expressed the highest levels of Ly-9, whereas the rest of B-cell lines
expressed low levels (Table 1). Analysis of several samples of
B-cell malignancies, corresponding to various stages of B-cell
maturation, showed that human Ly-9 was expressed on most of
them (Table 2), indicating that human Ly-9 is a pan–B-cell marker.
T-cell line Jurkat also expressed significant amounts of human
Ly-9. Myelomonocytic cell lines HL60 and U937 and erythromy-
eloid cell line K562 were negative for Ly-9 (Table 1). However,
half the acute myeloblastic leukemias tested were positive for Ly-9
(Table 2).
Immunoprecipitation of human Ly-9 from 300.19 cells
transfectants and B cell-line Daudi with anti–human
Ly-9 monoclonal antibodies
We performed immunoprecipitations from biotinylated untrans-
fected or human Ly-9 cDNA-transfected 300.19 cells using the
anti–human Ly-9 mAb (Figure 10). The mAb precipitated a
single band of approximately 120 kd in reducing and nonreduc-
ing conditions. In contrast, when the same antibodies were used
to precipitate human Ly-9 from the B-cell line Daudi, 2 bands of
120 kd and 100 kd were seen (Figure 10A). The second band
was similar to that detected when 300.19 cells were transfected
with the isoform that lacks the fourth immunoglobulinlike
domain. To test whether the second band found in Daudi cells
corresponded to an alternatively spliced form of Ly-9, RT-PCR
was performed with RNA isolated from Daudi cells. Two major
bands were detected (Figure 10B), and, after subcloning and
Figure 4. Monoclonal antibody reactive with the protein product of the human
Ly-9 full-length cDNA. 300.19 cells transfected with HLy-9 cDNA were examined
using the mAbs HLy-9.1.25, HLy-9.1.38, HLy-9.1.77, and HLy-9.1.84 in indirect
immunofluorescence assays with flow cytometric analysis. Fluorescence histograms
generated using 300.19 transfected cells are shown as solid lines. Staining of the
300.19 untransfected cells are shown as dotted lines. Fluorescence intensity is
shown on a 3-decade log scale.
Figure 5. Ontogeny of human Ly-9 in the thymus. Flow cytometric analysis of
human isolated thymocytes were incubated with biotinylated HLy-9.1.84 mAb,
CD4-FITC, and CD8 perCP, then washed and incubated with avidin PE.
Figure 6. Four-color flow cytometric analysis of human thymocyte cell
surface staining with anti–human Ly-9 mAb. Isolated thymocytes were
incubated with biotinylated HLy-9.1.84 mAb, CD4-FITC, CD8 perCP, and CD3-
APC and then washed and incubated with avidin PE. Bar indicates the cutoff of
the negative control.
Figure 7. Two-color flow cytometric analysis of human thymocyte cell surface
staining with anti–human Ly-9 mAb and CD69-FITC. Isolated thymocytes were
incubated with biotinylated HLy-9.1.84 mAb and CD69-FITC washed and incubated
with avidin phycoerythrin.
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sequencing, they were shown to encode the full-length cDNA
and an alternatively spliced isoform lacking the fourth immuno-
globulinlike domain, respectively. The sequence of 20 indepen-
dent clones of the lower band showed that they all lacked the
sequence corresponding to the fourth domain. Thus, the spliced
variant isolated from the cDNA might have been expressed on
the surface of certain B cells.
Discussion
This paper describes the cloning and characterization of the human
surface molecule Ly-9. We report the isolation of cDNA encoding
full-length human Ly-9 from a human Raji cDNA library. Unlike
the recently reported human Ly-9 cDNA sequence,21 our cDNA
sequence contains the complete leader sequence and part of the
cytoplasmic domain. In contrast with the published sequence, our
results show that mouse and human leader peptides have the same
number of amino acids (Figures 1, 2). Although the predicted
leader peptide of both human and mouse Ly-9 is long, some other
cell-surface protein, including CD49e, CD62P, CD163, and CD129,
have been shown to contain long leader peptides of 40 or more
amino acids.
The number of amino acids of the cytoplasmic tail is identical in
Figure 8. Flow cytometric analysis of human peripheral blood leukocytes and
bone marrow cells staining with anti–human Ly-9 mAb. These results are
representative of those obtained in at least 6 experiments for blood samples and 3 for
the bone marrow cells. PBL indicates peripheral blood leukocyte. (A) Peripheral blood
mononuclear cells (PBMCs) were incubated with biotinylated HLy-9.1.84 mAb and
CD19-FITC, CD3-APC, CD4-FITC, or CD8-perCP washed and incubated with avidin
PE. (B) PBMCs were incubated with biotinylated HLy-9.1.84 mAb and CD56-FITC
and CD16-PE washed and incubated with avidin-Cy-Chrome. (C) Bone marrow cells
were stained with biotinylated HLy-9.1.84 mAb and CD19-FITC washed and
incubated with avidin-PE. Cells with forward and light scatter characteristics of
lymphocytes were gated for experiments shown in panels A, B, and C. (D) Peripheral
blood cells were stained with biotinylated HLy-9.1.84 mAb washed and incubated
with avidin-PE. Cells with forward and light scatter characteristics of monocytes or
granulocytes were gated. Dotted lines indicate staining of the negative control in
histograms.
Figure 9. Flow cytometric analysis of human tonsil cell surface staining with
anti–human Ly-9 mAb. Cells were incubated with biotinylated HLy-9.1.84 mAb, CD19-
FITC, and CD3-APC washed and incubated with avidin phycoerythrin (upper panel) and
with IgD-FITC, CD38-PE, CD3-APC and incubated with avidin perCP (lower panel).
Table 1. Expression of human Ly-9 on lymphoid and myeloid cell lines
Positive cells
(%)
Log mean fluorescence
intensity
Raji 76.4 31.10
Daudi 99.8 36.09
CESS 90.5 21.96
BEN* 76.3 18.95
RPMI 8222 21.0 7.08
JM1 13.1 4.75
Jurkat 76.0 17.37
HSB2 7.5 4.17
HL60 4.1 3.79
U937 5.4 4.20
K562 12.5 4.32
Cells were stained with biotinylated HLy-9.1.84 mAb. This was followed by
incubation with avidin-phycoerythrin and analysis by flow cytometry. An unreac-
tive mAb was used as negative control. Results represent the percentage of
positive cells and the mean of fluorescence intensity. Positive staining appears
in boldface.
Table 2. Expression of human Ly-9 on hematopoietic malignancies
B-cell malignancies
ALL 2/2
CLL 12/15
MCL 5/5
HCL 1/2
MM 4/4
T-cell malignancies
ALL 1/1
Se´zary 1/1
Acute myeloid leukemia
AML 8/16
ALL indicates acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia;
MCL, mast cell leukemia; HCL, hairy cell leukemia; MM, multiple myeloma; AML,
acute myeloid leukemia.
Cells were stained with biotinylated HLy-9.1.84 mAb. This was followed by
incubation with avidin-phycoerythrin and analysis by flow cytometry. An unreactive
mAb was used as negative control. Results represent positive samples versus
analyzed samples.
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mouse and human, except for one amino acid.11,29 The lack of 14
amino acids in the cDNA reported elsewhere may be due to mRNA
splicing.29 Whether the presence of a spliced variant of the
cytoplasmic tail has any biologic significance remains unclear.
However, it may have, because the spliced sequence contains 2
threonines, 2 serines, and 1 tyrosine in a YxxL putative SH2-
binding motif (Figure 2). Two other tyrosine residues in the
cytoplasmic tail of human and mouse Ly-9 are in a motif in
agreement with the consensus sequence T-F-Y-X-X-V/I for the
binding of SAP and SHP-2, found in SLAM and 2B4.18-20 This
observation suggests that SAP and SHP-2 or other related SH2-
binding domain proteins may bind to Ly-9.
Northern blot analysis showed the expression of a 2.6-kb Ly-9
mRNA in lymphoid tissues. The pattern of expression is consistent
with that of mouse Ly-9, which is found on mature T and B
lymphocytes and thymocytes.3-5 Slightly differently sized bands
between 2.3 and 2.6 kb were observed in most lymphoid tissues
and might represent alternatively spliced mRNA encoding several
isoforms of the molecule.
Four mAbs were generated by immunizing mice with a stable
transfectant of human Ly-9. These mAbs stained 300.19 pre-B-cell
line transfected with human Ly-9 cDNA but did not stain untrans-
fected 300.19 cells. Using these mAbs, we showed that human
Ly-9 protein was expressed on the cell surfaces of thymocytes. The
expression of Ly-9 seems to have preceded positive selection
during T-cell differentiation because Ly-9 appeared before CD69.
CD69 is known to appear on thymocyte surfaces that have
undergone positive selection.30 In addition, peripheral blood and
tonsil T and B lymphocytes expressed significant levels of human
Ly-9. The intensity of expression of human Ly-9 on B cells was
lower than on T lymphocytes. Bone marrow B cells expressed low
levels of human Ly-9, indicating that its expression increased with
cell maturation. Most B-cell lines, leukemias, and lymphomas
expressed human Ly-9. All multiple myeloma samples analyzed
were positive for Ly-9, indicating that its expression is not lost
during differentiation to plasma cells, whereas most differentiation
antigens expressed on B cells were no longer expressed on terminally
differentiated plasma cells. Monocytes, granulocytes, erythrocytes, and
platelets did not express significant amounts of human Ly-9. Overall,
these results suggest that the expression of human Ly-9 is restricted to
lymphocytes. However, a significant number of acute myeloblastic
leukemias expressed human Ly-9, indicating that some cells of the
myeloid lineage also express human Ly-9.
The anti–human Ly-9 mAbs specifically immunoprecipitated a
single polypeptide of 120 kd from the cells transfected with full-length
cDNA. However, when Ly-9 was immunoprecipitated from the B-cell
line Daudi, 2 bands of 120 kd and 100 kd could be observed. The
smaller band is probably a spliced form of the molecule lacking the
fourth immunoglobulinlike domain.Aband of similar size was observed
when anti–human Ly-9 mAbs were used to immunoprecipitate this
protein with cells transfected with the cDNA of clone HLy-9 D4, which
lacks the fourth immunoglobulinlike domain. Minor bands are present
in anti–human Ly-9 immunoprecipitates from resting peripheral blood
lymphocytes and thymocytes (data not shown). These smaller bands
were also observed in the initial description of mouse Ly-9 and were
attributed to differences in the level of glycosylation.3 In contrast, we
believe that these bands result from alternatively spliced Ly-9 mRNAs.
RT-PCR in Daudi cells showed the presence of 2 major bands. They
corresponded to the full-length cDNA and a spliced variant lacking the
fourth immunoglobulinlike domain of Ly-9. Nevertheless, the contribu-
tion of phosphorylation and glycosylation to the heterogeneity of bands
remains to be elucidated.
Thymocytes and B and T lymphocytes express a previously
undescribed glycoprotein representing the human homologue of
mouse Ly-9. This protein can be used as a surface marker to study
lymphocyte differentiation. The mAbs generated in this study may
improve our understanding of the pattern of expression of Ly-9 and
the delineation of the cytoplasmic and cell-surface molecules with
which it may interact. These mAbs will be useful to establish
hypotheses regarding the biologic roles of this molecule in
lymphocyte development and activation.
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Figure 10. Immunoprecipitation and isoforms of cell surface human Ly-9
protein. (A) Detergent lysates of surface-labeled Daudi cell line, 300.19 cells
transfected with full-length human Ly-9 cDNA, Ly-9 cDNA lacking the fourth
immunoglobulinlike domain (HLy-9-D4), and 300.19 untransfected cells were
immunoprecipitated with the HLy-9.1.25 mAb and analyzed under reducing and
nonreducing conditions on a 10% sodium dodecyl sulfate–polyacrylamide gel.
Molecular weights (kd) were determined by the migration of a known protein
standard. (B) cDNA was made with mRNA from 300.19 cells transfected with
full-length human Ly-9 cDNA, Ly-9 cDNA lacking the fourth immunoglobulinlike
domain (HLy-9-D4), and B-cell line Daudi. Ethidium bromide staining of the PCR
products after gel analysis. A molecular weight ladder is shown as an estimate of
DNA band size.
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